Attenzione: i dati modificati non sono ancora stati salvati. Per confermare inserimenti o cancellazioni di voci è necessario confermare con il tasto SALVA/INSERISCI in fondo alla pagina
IRIS
Little is known about the characteristics and treatments of patients with severe asthma across Europe, but both are likely to vary. This is the first study in the European Respiratory Society Severe Heterogeneous Asthma Research collaboration, Patient-centred (SHARP) Clinical Research Collaboration and it is designed to explore these variations. Therefore, we aimed to compare characteristics of patients in European severe asthma registries and treatments before starting biologicals. This was a cross-sectional retrospective analysis of aggregated data from 11 national severe asthma registries that joined SHARP with established patient databases. Analysis of data from 3236 patients showed many differences in characteristics and lifestyle factors. Current smokers ranged from 0% (Poland and Sweden) to 9.5% (Belgium), mean body mass index ranged from 26.2 (Italy) to 30.6 kg·m−2 (the UK) and the largest difference in mean pre-bronchodilator forced expiratory volume in 1 s % predicted was 20.9% (the Netherlands versus Hungary). Before starting biologicals patients were treated differently between countries: mean inhaled corticosteroid dose ranged from 700 to 1335 µg·day−1 between those from Slovenia versus Poland when starting anti-interleukin (IL)-5 antibody and from 772 to 1344 µg·day−1 in those starting anti-IgE (Slovenia versus Spain). Maintenance oral corticosteroid use ranged from 21.0% (Belgium) to 63.0% (Sweden) and from 9.1% (Denmark) to 56.1% (the UK) in patients starting anti-IL-5 and anti-IgE, respectively. The severe asthmatic population in Europe is heterogeneous and differs in both clinical characteristics and treatment, often appearing not to comply with the current European Respiratory Society/American Thoracic Society guidelines definition of severe asthma. Treatment regimens before starting biologicals were different from inclusion criteria in clinical trials and varied between countries.
Characteristics and treatment regimens across ERS SHARP severe asthma registries / van Bragt, J. J. M. H.; Adcock, I. M.; Bel, E. H. D.; Braunstahl, G. -J.; ten Brinke, A.; Busby, J.; Canonica, G. W.; Cao, H.; Chung, K. F.; Csoma, Z.; Dahlen, B.; Davin, E.; Hansen, S.; Heffler, E.; Horvath, I.; Korn, S.; Kots, M.; Kuna, P.; Kwon, N.; Louis, R.; Plaza, V.; Porsbjerg, C.; Ramos-Barbon, D.; Richards, L. B.; Skrgat, S.; Sont, J. K.; Vijverberg, S. J. H.; Weersink, E. J. M.; Yasinska, V.; Wagers, S. S.; Djukanovic, R.; Maitland-Van der Zee, A. H.; Abenhardt, B.; Adler, J.; Alfonso, R.; Ali, R.; Alkameh, S.; Almonacid Sanchez, C.; Alvares, L.; Anderson, G.; Assing, K.; Ayre, S.; Becker, J.; Bergmann, K.; Bieksiene, K.; Bjerring, N.; Blasi, F.; Bloemen, P.; Blum, H.; Boing, S.; Bonavia, M.; Bossios, A.; Bourdin, A.; Brons, A.; Brusselle, G.; Buis, J.; Caiaffa, M.; Calabrese, C.; Camiciottoli, G.; Caruso, C.; Castilla Martinez, M.; Centanni, S.; Cisneros Serrano, C.; Corsico, A.; Cosmi, L.; Costantino, M.; Costello, R.; Crimi, N.; Dahlen, S.; D'Amato, M.; Davies, D.; de Borja Garcia-Cosio Piqueras, F.; Decarlo, G.; Deimling, A.; Del Giacco, S.; Diaz Campos, R.; Djandji, M.; Doberer, D.; Dupont, L.; Dyett, K.; Edelbaher, N.; Edelmann, M.; Ehmann, R.; Ekberg-Jansson, A.; Farsi, A.; Favero, E.; Feimer, J.; Fletcher, M.; Foschino, B.; Frankemolle, B.; Gaga, M.; Gappa, M.; Garcia de Pedro, J.; Garcia Rivero, J.; Gasplmayr, M.; Gebhardt, R.; Geldmacher, H.; Geltner, C.; Gerstlauer, M.; Gibson, T.; Giuseppe, G.; Gogoll, C.; Grimm-Sachs, V.; Grisle, I.; Grun, B.; Grunewaldt, A.; Guarnieri, G.; Gullon Blanco, J.; Hamelmann, E.; Hamerlijnck, D.; Hammers-Reinhard, A.; Hanon, S.; Harzheim, D.; Heaney, L.; Hellmich, S.; Herden, M.; Hering, T.; Herth, F.; Hilberg, O.; Howarth, P.; Hubatsch, M.; Humbert, M.; Husemann, K.; Idzko, M.; Jackson, D.; Jandl, M.; Jaumont, X.; Joos, G.; Jost, M.; Juch, M.; Kabesch, M.; Kaiser-Labusch, P.; Kardos, P.; Kassner, F.; Keeley, T.; Kerr, W.; Kirschner, J.; Klimek, L.; Koca, M.; Koczulla, R.; Koerner-Rettberg, C.; Kopac, P.; Kronsbein, J.; Kuprys Lipinska, I.; Langer, M.; Langeveld, B.; Lantz, A.; Lazarinis, N.; Lazic, Z.; Lehtimaki, L.; Leuppi, J.; Lombardi, C.; Lommatzsch, M.; Lopez-Vina, A.; Luca, R.; Ludviksdottir, D.; Luttecke-Hecht, C.; Macchia, L.; Magni, T.; Martinez Rivera, C.; Mastoridis, P.; Mazza, F.; Menzella, F.; Menzies-Gow, A.; Michils, A.; Mihalthan, F.; Milanese, M.; Milger-Kneidinger, K.; Molinska, J.; Montagna, I.; Montuschi, P.; Mulleneisen, N.; Munoz Esquerre, M.; Nanzer-Kelly, A.; Nenasheva, N.; Neurohr, C.; Nucera, E.; Otker, J.; Oud, K.; Paggiaro, P.; Parente, R.; Parkinson, J.; Passalacqua, G.; Patberg, N.; Patella, V.; Patino, O.; Paulsson, T.; Peche, R.; Pelaia, G.; Peress, E.; Perez de Llano, L.; Pfeffer, P.; Pfister, P.; Pilette, C.; Pinedo Sierra, C.; Pini, L.; Powitz, F.; Ranger, T.; Rasmussen, L.; Rasmussen, K.; Rezelj, M.; Ricciardi, L.; Ricciardolo, F.; Ridolo, E.; Rijssenbeek-Nouwens, L.; Rolla, G.; Romero Ribate, D.; Rudiger, S.; Safioti, G.; Sandstrom, T.; Santus, P.; Sauer, R.; Schauerte, G.; Schipmann, R.; Schleich, F.; Schmid, J.; Schmidt, F.; Schmidt, O.; Schmitz, M.; Schrag, T.; Schroer, S.; Schultz, K.; Schulz, C.; Scichilone, N.; Sedlak, V.; Selb, J.; Senna, G.; Sergejeva, S.; Serrano Pariente, J.; Sichau, M.; Simona, D.; Singer, A.; Skowasch, D.; Smeenk, F.; Smith, S.; Solidoro, P.; Spadaro, G.; Spanevello, A.; Stefansdottir, M.; Steinmetz, K.; Steiss, J.; Stephan, M.; Stieglitz, S.; Suhling, H.; Taube, C.; Tolga Yavuz, S.; Tudoric, N.; Ulrik, C.; van de Ven, M.; van den Elshout, F.; van Dyke, M.; van Nederveen-Bendien, S.; van Veen, I.; Vandenplas, O.; Velthove, K.; Vianello, A.; Vogelberg, C.; Wallen-Nielsen, E.; Wisskirchen, T.; Yacoub, M.; Yancey, S.; Zappa, M.; Zielen, S.; Zimmermann, C.; Zimmermann, R.. - In: EUROPEAN RESPIRATORY JOURNAL. - ISSN 0903-1936. - 55:1(2020), p. 1901163. [10.1183/13993003.01163-2019]
Characteristics and treatment regimens across ERS SHARP severe asthma registries
Little is known about the characteristics and treatments of patients with severe asthma across Europe, but both are likely to vary. This is the first study in the European Respiratory Society Severe Heterogeneous Asthma Research collaboration, Patient-centred (SHARP) Clinical Research Collaboration and it is designed to explore these variations. Therefore, we aimed to compare characteristics of patients in European severe asthma registries and treatments before starting biologicals. This was a cross-sectional retrospective analysis of aggregated data from 11 national severe asthma registries that joined SHARP with established patient databases. Analysis of data from 3236 patients showed many differences in characteristics and lifestyle factors. Current smokers ranged from 0% (Poland and Sweden) to 9.5% (Belgium), mean body mass index ranged from 26.2 (Italy) to 30.6 kg·m−2 (the UK) and the largest difference in mean pre-bronchodilator forced expiratory volume in 1 s % predicted was 20.9% (the Netherlands versus Hungary). Before starting biologicals patients were treated differently between countries: mean inhaled corticosteroid dose ranged from 700 to 1335 µg·day−1 between those from Slovenia versus Poland when starting anti-interleukin (IL)-5 antibody and from 772 to 1344 µg·day−1 in those starting anti-IgE (Slovenia versus Spain). Maintenance oral corticosteroid use ranged from 21.0% (Belgium) to 63.0% (Sweden) and from 9.1% (Denmark) to 56.1% (the UK) in patients starting anti-IL-5 and anti-IgE, respectively. The severe asthmatic population in Europe is heterogeneous and differs in both clinical characteristics and treatment, often appearing not to comply with the current European Respiratory Society/American Thoracic Society guidelines definition of severe asthma. Treatment regimens before starting biologicals were different from inclusion criteria in clinical trials and varied between countries.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11381/2888704
Citazioni
ND
56
50
social impact
Conferma cancellazione
Sei sicuro che questo prodotto debba essere cancellato?
simulazione ASN
Il report seguente simula gli indicatori relativi alla propria produzione scientifica in relazione alle soglie ASN 2023-2025 del proprio SC/SSD. Si ricorda che il superamento dei valori soglia (almeno 2 su 3) è requisito necessario ma non sufficiente al conseguimento dell'abilitazione. La simulazione si basa sui dati IRIS e sugli indicatori bibliometrici alla data indicata e non tiene conto di eventuali periodi di congedo obbligatorio, che in sede di domanda ASN danno diritto a incrementi percentuali dei valori. La simulazione può differire dall'esito di un’eventuale domanda ASN sia per errori di catalogazione e/o dati mancanti in IRIS, sia per la variabilità dei dati bibliometrici nel tempo. Si consideri che Anvur calcola i valori degli indicatori all'ultima data utile per la presentazione delle domande.
La presente simulazione è stata realizzata sulla base delle specifiche raccolte sul tavolo ER del Focus Group IRIS coordinato dall’Università di Modena e Reggio Emilia e delle regole riportate nel DM 589/2018 e allegata Tabella A. Cineca, l’Università di Modena e Reggio Emilia e il Focus Group IRIS non si assumono alcuna responsabilità in merito all’uso che il diretto interessato o terzi faranno della simulazione. Si specifica inoltre che la simulazione contiene calcoli effettuati con dati e algoritmi di pubblico dominio e deve quindi essere considerata come un mero ausilio al calcolo svolgibile manualmente o con strumenti equivalenti.